NeuroMetrix (NURO) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $769,148, down over 53% year-over-year, mainly due to a sharp decline in DPNCheck sales following Medicare Advantage rule changes.

• Quell product line posted 47% year-over-year revenue growth to $192,000, driven by fibromyalgia demand.

• Strategic review process is ongoing, with no transactions yet deemed in shareholders' best interest; options include marketing changes, asset sales, or a merger.

• Substantial reduction in force implemented, lowering operating expenses by over $500,000 per quarter.

• Added a new independent director and terminated the ATM equity facility in April 2024.

Financial highlights

• Gross profit for Q2 2024 was $491,919, with a gross margin of 64%, down from 67.6% in Q2 2023.

• Net loss for Q2 2024 was $1.49 million ($0.74 per share), slightly improved from a $1.54 million loss in Q2 2023.

• Operating expenses totaled $2.3 million, down about 15% year-over-year, reflecting cost reductions.

• Operating cash usage was $1.4 million, $90,000 lower than Q2 2023.

• Liquid assets at quarter-end were $16.4 million; working capital was $16.9 million.

Outlook and guidance

• Quell OTC business to restart in Q4 2024, aiming for two growth sources.

• De novo submission for Quell CIPN indication planned by Q4 2024, with potential commercial launch by end of 2025.

• DPNCheck business expected to remain challenged; new market opportunities being pursued, with international sales expected to recover later in 2024.

• Current cash and securities expected to fund operations for at least the next twelve months.

• VA health system uptake for Quell Fibromyalgia expected to be a core focus in 2025.